Tiziana Life Sciences Ltd. announced for the first time, quantitative data showing improvement in White Matter Z scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis (na-SPMS). White Matter Z scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.744 USD | +9.25% | +19.48% | +32.86% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+32.86% | 68.31M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab